HUTCHMED (CHINA) LIMIT

18.43

27-November-24 16:45:00

15 minutes delayed

Stocks

+1.05

+6.04%

Today's range

18.29 - 18.57

ISIN

N/A

Source

NASDAQ

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

24 Mar 2021 09:30:00 By Nasdaq GlobeNewswire
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

24 Mar 2021 03:00:00 By Nasdaq GlobeNewswire
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

04 Mar 2021 07:00:02 By Nasdaq GlobeNewswire
Chi-Med to Announce 2020 Final Results

03 Feb 2021 02:00:00 By Nasdaq GlobeNewswire
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

14 Jan 2021 05:00:00 By Nasdaq GlobeNewswire
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

10 Jan 2021 20:00:00 By Nasdaq GlobeNewswire

<<
<
4
5
6
7
8
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.